Precision BioSciences Inc. 8-K Summary
Business Context and Reporting Period
Precision BioSciences, Inc. (DTIL), an emerging growth company incorporated in Delaware, filed this Current Report on Form 8-K on May 8, 2024. The filing discloses a definitive subscription agreement for a non-brokered private placement of common stock to company management.
Key Financial Metrics and Transaction Details
- Transaction Type: Private placement of 25,000 shares of common stock.
- Offering Price: $12.00 per share (a 13.5% premium to the closing price immediately preceding the agreement).
- Gross Proceeds: Approximately $300,000.
- Use of Proceeds: Funding ongoing research and development initiatives.
- Investors:
- Michael Amoroso (CEO): 8,334 shares ($100,008).
- Alex Kelly (CFO): 8,334 shares ($100,008).
- Dario Scimeca (General Counsel): 833 shares ($9,996).
- Jeff Smith (Chief Research Officer): 833 shares ($9,996).
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity metrics as this report focuses solely on the capital raise event.
Material Changes
This filing represents a material change in the company's capital structure through the issuance of new shares to insiders. The transaction is expected to close on May 8, 2024, subject to customary closing conditions.
Guidance, Outlook, and Risks
Management intends to utilize the net proceeds to support research and development. The filing includes standard forward-looking statements regarding the timing, size, and consummation of the private placement. Risks include uncertainties related to market conditions, the satisfaction of closing conditions, and general economic factors. The company undertakes no obligation to update these statements.
Investor Verification Checklist
- Confirm the closing of the private placement and receipt of the $300,000 in gross proceeds.
- Verify the specific allocation of funds to research and development projects in subsequent filings.
- Review the impact of the 25,000 new shares on total outstanding share count and potential dilution.
- Monitor the company's cash runway given the relatively small size of the capital raise relative to typical biotech R&D costs.